Serum index test %[-2]proPSA and prostate health index are more accurate than prostate specific antigen and %fPSA in predicting a positive repeat prostate biopsy

Journal of Urology

Volumn 188, Issue 4, 2012, Pages 1137-1143

  Lazzeri, Massimo ^a   Briganti, Alberto ^a   Scattoni, Vincenzo ^a   Lughezzani, Giovanni ^a   Larcher, Alessandro ^a   Gadda, Giulio Maria ^a   Lista, Giuliana ^a   Cestari, Andrea ^a   Buffi, Nicolòmaria ^a   Bini, Vittorio ^b   Freschi, Massimo ^a   Rigatti, Patrizio ^a   Montorsi, Francesco ^a   Guazzoni, Giorgio ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

Author keywords

biopsy; diagnosis; early detection of cancer; prostate specific antigen; prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TOTAL PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER DIAGNOSIS; COMPARATIVE STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HEALTH INDEX; PROSTATE SPECIFIC ANTIGEN ISOFORM P2PSA PERCENTAGE;

EID: 84866075913     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2012.06.017     Document Type: Article

References (22)

1. J. Heijnsdijk, A. der Kinderen, E.M. Wever Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer BJC 101 2009 1833
2. J. Raja, N. Ramachandran, G. Munneke Current status of transrectal ultrasound-guided prostate biopsy in the diagnosis of prostate cancer Clin Radiol 61 2006 142
3. EAU Guidelines on Prostate Cancer, 2011 Edition www.uroweb.org Accessed December 2011
4. L.S. Marks, Y. Fradet, I.L. Deras PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy Urology 69 2007 532
5. A. Haese, A. de laTaille, H. van Poppel Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy Eur Urol 54 2008 1081
6. M.J. Roobol Contemporary role of prostate cancer gene 3 in the management of prostate cancer Curr Opin Urol 21 2011 225
7. M.J. Roobol, F.H. Schröder, G.L. van Leenders Performance of prostate cancer antigen 3 (PCA3) and prostate-specific antigen in prescreened men: reproducibility and detection characteristics for prostate cancer patients with high PCA3 scores (< 100) Eur Urol 58 2010 893
8. T. Rhodes, D.J. Jacobson, M.E. McGree Distribution and associations of [-2]proenzyme-prostate specific antigen in community dwelling black and white men J Urol 187 2012 92
9. L.J. Sokoll, M.G. Sanda, Z. Feng A prospective, multicenter, National Cancer Institute Early Detection Research Network Study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness Cancer Epidemiol Biomarkers Prev 19 2010 1193
10. B.V. Le, C.R. Griffin, S. Loeb [-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study J Urol 183 2010 1355
11. F.H. Jansen, R.H. Van Schaik, J. Kurstjens Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves the diagnostic accuracy in prostate cancer detection Eur Urol 57 2010 921
12. G. Guazzoni, L. Nava, M. Lazzeri Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting Eur Urol 60 2011 214
13. W.J. Catalona, A.W. Partin, M.G. Sanda A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range J Urol 185 2011 1650
14. A. Semjonow, T. Köpke, E. Eltze Pre-analytical in-vitro stability of [-2]proPSA in blood and serum Clin Biochem 47 2010 926
15. V. Scattoni, M. Raber, F. Abdollah Biopsy schemes with the fewest cores for detecting 95% of the prostate cancers detected by a 24-core biopsy Eur Urol 57 2010 1
16. J.I. Epstein, W.C. Allsbrook Jr, M.B. Amin The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma Am J Surg Pathol 29 2005 1228
17. D.W. Hosmer, S. Lemeshow Applied Logistic Regression 2000 John Wiley & Sons New York
18. E.R. DeLong, D.M. DeLong, D.L. Clarke-Pearson Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach Biometrics 44 1988 837
19. A.J. Vickers, E.B. Elkin Decision curve analysis: a novel method for evaluating prediction models Med Decis Making 26 2006 565
20. W.J. Catalona, A.W. Partin, K.M. Slawin Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial JAMA 279 1998 1542
21. B. Djavan, A. Zlotta, M. Remzi Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men J Urol 163 2000 1144
22. G. Guazzoni, M. Lazzeri, G. Lughezzani Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer Eur Urol 61 2012 455